President Donald Trump on Thursday unveiled a deal with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for their popular obesity treatments Zepbound and Wegovy, along with insulin, migraine, and diabetes drugs.
The weight loss drugs are part of a new generation of obesity medications known as GLP-1 receptor agonists that have soared in popularity in recent years. Access to the drugs has been limited because of their cost and insurance coverage.
What Does the Deal Entail?
A fact sheet released by the White House stated that the prices of Ozempic and Wegovy, which are made by Novo Nordisk and contain the GLP-1 agonist semaglutide as the active ingredient, will drop significantly.
We had a problem loading this article. Please enable javascript or use a different browser. If the issue persists, please visit our help center.
